mFOLFOX6 + dabrafenib + cetuximab + panitumumab

This is a **combination regimen** consisting of **mFOLFOX6** (a modification of FOLFOX that includes oxaliplatin, folinic acid/leucovorin, and fluorouracil), **dabrafenib** (a BRAF inhibitor), **cetuximab** (an anti-EGFR monoclonal antibody), and **panitumumab** (an anti-EGFR monoclonal antibody). - mFOLFOX6 is a chemotherapy backbone commonly used for gastrointestinal cancers, particularly colorectal cancer, and exerts cytotoxic effects by interrupting DNA synthesis and repair in rapidly dividing cells[2][3][4]. - Dabrafenib is a selective inhibitor of BRAF kinase (specifically BRAF V600E mutation), used mainly in melanoma and under investigation for other solid tumors. - Cetuximab and panitumumab are monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) on cancer cells, inhibiting downstream signaling and tumor proliferation. Combination of multiple anti-EGFR antibodies (cetuximab and panitumumab) with a BRAF inhibitor and cytotoxic chemotherapy is a novel approach under investigation for BRAF-mutated and/or EGFR-driven cancers, primarily metastatic colorectal cancer. This type of regimen is used in clinical trials and is not a standard, marketed therapy.